Andre Roggan - Olympus Ex CTO
| OCPNF Stock | USD 16.00 0.00 0.00% |
Insider
Andre Roggan is Ex CTO of Olympus
| Phone | 81 3 3340 2111 |
| Web | https://www.olympus-global.com |
Olympus Management Efficiency
The company has return on total asset (ROA) of 0.0815 % which means that it generated a profit of $0.0815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2329 %, meaning that it generated $0.2329 on every $100 dollars invested by stockholders. Olympus' management efficiency ratios could be used to measure how well Olympus manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Augustine JD | Hoya Corp | 55 | |
| Dorthe Ronnau | Coloplast AS | 57 | |
| Ellen Bjurgert | Coloplast A | N/A | |
| Steven MD | Carl Zeiss Meditec | N/A | |
| Euan Thomson | Carl Zeiss Meditec | 60 | |
| Ariel Bauer | Essilor International SA | N/A | |
| Francesco Milleri | Essilor International SA | 64 | |
| Tomoko Nakagawa | Hoya Corp | N/A | |
| Giorgio Iannella | Essilor International SA | N/A | |
| Martin Wiechmann | Carl Zeiss Meditec | N/A | |
| Dennis Kaysen | Coloplast AS | N/A | |
| Ellen Bjurgert | Coloplast AS | N/A | |
| Laurie Ferguson | Carl Zeiss Meditec | N/A | |
| Marco Catalani | Essilor International SA | N/A | |
| Dorthe Ronnau | Coloplast A | 57 | |
| Mike Wang | Carl Zeiss Meditec | N/A | |
| Stefano Grassi | Essilor International SA | 50 | |
| Kensuke Lizuka | Sysmex Corp | N/A | |
| Andrew Chang | Carl Zeiss Meditec | N/A | |
| Markus Weber | Carl Zeiss Meditec | N/A | |
| Richard Rosenzweig | AngioDynamics | 57 | |
Management Performance
| Return On Equity | 0.23 | |||
| Return On Asset | 0.0815 |
Olympus Leadership Team
Elected by the shareholders, the Olympus' board of directors comprises two types of representatives: Olympus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Olympus. The board's role is to monitor Olympus' management team and ensure that shareholders' interests are well served. Olympus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Olympus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stefan Kaufmann, Executive Officer | ||
| Chikashi Takeda, Ex CFO | ||
| Andre Roggan, Ex CTO | ||
| Yasuo Takeuchi, Sr. Executive Managing Officer, Head of Corporate Management Office and Director | ||
| Nacho Abia, Executive Officer | ||
| Stephen Kneebone, Co Officer | ||
| Donna Miller, Head Counsel | ||
| Tetsuo Kobayashi, Executive Officer | ||
| Takaaki Sakurai, VP Relations | ||
| Shigeto Ohtsuki, Co Head |
Olympus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Olympus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.23 | |||
| Return On Asset | 0.0815 | |||
| Current Valuation | 25.72 B | |||
| Shares Outstanding | 1.27 B | |||
| Shares Owned By Insiders | 4.42 % | |||
| Shares Owned By Institutions | 59.82 % | |||
| Price To Earning | 29.76 X | |||
| Price To Book | 5.27 X | |||
| Price To Sales | 0.03 X | |||
| Revenue | 868.87 B |
Currently Active Assets on Macroaxis
Other Information on Investing in Olympus Pink Sheet
Olympus financial ratios help investors to determine whether Olympus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Olympus with respect to the benefits of owning Olympus security.